0001903784

IPO filing research

Vogenx, Inc.

Pharmaceutical Preparations

ipo amended Nasdaq Capital Market S-1

Vogenx, Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1 on 2026-07-15. Current deal snapshot: exchange Nasdaq Capital Market.

Filing Timeline

SEC EDGAR

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Common Stock · Exchange Nasdaq Capital Market · Ticker VOGX · Underwriters Jones

Vogenx, Inc. outlines significant reliance on third-party collaborators and contractors for clinical trials, manufacturing, and product development. The company faces challenges in securing collaborations, regulatory approvals, and managing dependencies on external partners, which could delay product development and commercialization. Key risks include potential failures in third-party performance, manufacturing delays, and difficulties in scaling production. The filing emphasizes the need for substantial capital and the impact of external factors like market consolidation on collaboration opportunities.

2026-07-15 · 0001185185-26-002985

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

2026-06-30 · 0001185185-26-002747

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

2026-04-02 · 0001185185-26-001233

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

2026-02-20 · 0001185185-26-000633

Comparable Deals

16 comparable deals

Healthcare & BiotechLast 18 months

Only 0 strict matches; expanded to 16 using nearest neighbors.

Showing top 8 by similarity.

-1.3%

Median day-1

50%

Above issue

-1.3%

Median week-1

-20.9%

Downside (p10)

Kardigan, Inc. KARD

2026-06-18 $400M Day 1: +37.5% Wk 1: +41.1%

same SICrecent IPO

Parabilis Medicines, Inc. PBLS

2026-06-10 $670M Day 1: +58.0% Wk 1: +30.2%

same SICrecent IPO

Seaport Therapeutics, Inc. SPTX

2026-05-01 $255M Day 1: +10.2% Wk 1: -13.9%

same SICrecent IPO

Avalyn Pharma Inc. AVLN

2026-04-30 $300M Day 1: +63.8% Wk 1: +53.9%

same SICrecent IPO

First Tracks Biotherapeutics, Inc. TRAX

2026-04-20 - Day 1: -9.3% Wk 1: -11.5%

same SICrecent IPO

Kailera Therapeutics, Inc. KLRA

2026-04-17 $625M Day 1: +62.5% Wk 1: +56.7%

same SICrecent IPO

Generate Biomedicines, Inc. GENB

2026-02-27 $400M Day 1: -20.9% Wk 1: -22.2%

same SICrecent IPO

Aardvark Therapeutics, Inc. AARD

2026-02-06 $94M Day 1: -20.9% Wk 1: -23.3%

same SICrecent IPO

Recent News

No recent news stored for this issuer.